Outcome Following Truncation of Asparaginase

Status Completed

Clinical Trial Summary

This study aimed to investigate the outcome of patients who had their asparaginase treatment truncated in the NOPHO ALL2008 protocol.

Clinical Trial Description

Overall survival for children with ALL is now above 90% in several protocols, but asparaginase associated toxicities still constitutes a significant problem as they, besides causing acute morbidity and mortality, can cause truncation of treatment with a subsequent increased risk of relapse. The most frequent toxicities causing asparaginase truncations are hypersensitivity, pancreatitis and thrombosis. Especially hypersensitivity constitutes a problem due to silencing antibodies, not only in patients with clinical hypersensitivity but also in patients without clinical symptoms (silent inactivation). In the NOPHO ALL2008 protocol asparaginase associated toxicities and truncation of asparaginase have been registered since the protocol opened in 2008. In addition asparaginase enzyme activity measurements have been done before every asparaginase administration and analyzed retrospectively. The primary aim of this study was to investigate if patients with truncation of asparaginase or lack of asparaginase enzyme activity had a different risk of relapse compared to patients who received full asparaginase treatment. Secondary we aimed to explore if patients who received less than 50% of their planned asparaginase dosages had a different risk of relapse compared to those who received 50% or more. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT03987542
Study type	Observational [Patient Registry]
Source	Aarhus University Hospital
Contact
Status	Completed
Phase
Start date	July 2008
Completion date	June 2020

View Details

See also
Status	Clinical Trial	Phase
Not yet recruiting	`NCT03964922` - Immunoevasive Tactics Employed by Myeloid Malignancy After Allogeneic Stem Cell Transplantation	N/A
Not yet recruiting	`NCT06385808` - Efficacy and Safety of MTBF Conditioning Regimen for Salvageable Allo-HSCT in the Treatment of R/R AML	N/A
Active, not recruiting	`NCT04139434` - Dose-Escalation Study of Oral Administration of LP-108 as Monotherapy and in Combination With Azacitidine in Patients With Relapsed or Refractory MDS, CMML, or AML	Phase 1
Recruiting	`NCT04282811` - Observational Study Relapsed or Refractory Chronic Lymphocytic Leukemia Venetoclax-based Regimens Outside Clinical Trials in Italy
Recruiting	`NCT03181815` - Cladribine in Combination With CAG in Patients With Refractory/Relapsed Acute Myeloid Leukemia	Phase 2
Recruiting	`NCT03091933` - Antiminor Histocompatibility Complex (MiHA) T Cells for Patients With Relapsed Hematologic Malignancies Following Matched HSCT (Guided Lymphocyte Immunopeptide Derived Expansion)	Phase 1/Phase 2
Recruiting	`NCT05164042` - Allogeneic CD19 CAR-T Cells for the Treatment of Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia	Phase 1/Phase 2
Completed	`NCT02028650` - Randomized Study of HLA-mismatched DSI to Treat Relapse Leukemia After HLA- Matched Transplantation	N/A
Recruiting	`NCT05512169` - Pharmacogenomic Association Study in Indian Children With Acute Lymphoblastic Leukemia
Recruiting	`NCT03799224` - Decitabine Plus mBU/CY Preconditioning for Relapse/Refractory Acute Leukemia	Phase 2/Phase 3
Recruiting	`NCT06006403` - Safety and Efficacy of CD123-targeted CAR-NK for Relapsed/Refractory Acute Myeloid Leukemia or Blastic Plasmacytoid Dendritic Cell Neoplasm	Phase 1/Phase 2
Completed	`NCT04835519` - Phase I/II Study of Enhanced CD33 CAR T Cells in Subjects With Relapsed or Refractory Acute Myeloid Leukemia	Phase 1/Phase 2